Biggest News Aggregation in the World
📰 Chemotype Evolution News

Chemotype Evolution News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Chemotype Evolution. Real-time updates on events, politics, business and more.

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to ...
United States Thomas Schinecker Levi Garraway Roche Pharmaceuticals Division Roche Group Carmot Therapeutics Inc

Roche Holding AG entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. frim shareholders for approximately $3.1 billion.

Roche Holding AG entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. frim shareholders for approximately $3.1 billion on December 4, 2023. Under the terms of the agreement,...
Roche Group Roche Holding Pharmaceuticals Division Carmot Therapeutics Inc Carmot Therapeutics Chemotype Evolution

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to ...
United States Levi Garraway Thomas Schinecker Carmot Therapeutics Inc Head Of Global Product Development Roche Pharmaceuticals Division

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Carmot's IPO Filing Makes Case for Bias in Drugging Key Obesity, Diabetes Targets

Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
United States Novo Nordisk Victoza Novo Nordisk Ozempic Eli Lilly Stig Hansen Heather Turner

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science